Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2018 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio Presents Iclaprim Data at ESCMID/ASM Conference

Iclaprim overview presented in State of the Art LectureSafety analysis of diabetic patients in REVIVE ABSSSI trials shows fewer adverse events versus vancomycinSurveillance data confirm in vitro...
August 17, 2018 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio to Present Iclaprim Data at ESCMID/ASM Conference

NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim...
August 14, 2018 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the U.S....
August 09, 2018 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio to Present at Investor Events in August and September

NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the...
August 08, 2018 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037

NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics,...
July 03, 2018 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors

NEW YORK, July 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that...
June 19, 2018 10:00 ET | Source: Motif BioSciences Inc.

Result of Annual General Meeting

NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the...
June 14, 2018 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio Submits NDA for Iclaprim

NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the...
June 11, 2018 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio Announces New Iclaprim Data Presented at ASM Microbe 2018

Pooled efficacy and safety data from REVIVE Phase 3 trials presentedData also published in peer-reviewed journal, International Journal of Antimicrobial Agents NEW YORK, June 11, 2018 (GLOBE...
May 31, 2018 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio to present at Jefferies Global Healthcare Conference in New York

NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the...